At the same time, the "Shanghai Listed Companies Corporate Social Responsibility Blue Book (2016)" was released at this summit. The blue book is composed of Xinhuanet, Shanghai Association of Listed Companies, Shanghai Federation of Economic Organizations, Shanghai Pudong New Area Financial Services Bureau, China The Financial Information Center, in conjunction with the Corporate Social Responsibility Research Center of the Economics Department of the Chinese Academy of Social Sciences, conducted research and analysis on the corporate social responsibility practice and information disclosure of listed companies (data at the end of 2015) and finally formed after investigating and analyzing 222 member units of the Shanghai Association of Listed Companies.

The Blue Book of Corporate Social Responsibility of Shanghai Listed Companies (2016), in accordance with internationally accepted standards, reveals the impact of company policies and business activities on society from three aspects of economy, environment and social performance, and calculates the scores of China’s corporate social responsibility reports , Rankings, and stage characteristics of the development of the corporate social responsibility report, and classify corporate social responsibility from one star to the highest five stars.

The Blue Book published the evaluation results of the social responsibility development index of Shanghai listed companies (hereinafter referred to as the development index evaluation) (2016) and the evaluation results of the social responsibility report of Shanghai listed companies (hereinafter referred to as the social responsibility report evaluation) (2016). In the two evaluation results, Fosun Pharma ranked second and first. At the same time, Fosun Pharma ranks first in the social responsibility development index of the pharmaceutical and biological industry in the hot industry social responsibility development index released by the blue book.

In the evaluation of the development index, the "four-in-one" theoretical model of responsibility management, market management, social responsibility, and environmental responsibility is used to collect Shanghai listings from corporate social responsibility reports, corporate annual reports, corporate individual reports, and corporate official websites. The company’s social responsibility information from 2015 to 2016, and its content analysis and quantitative evaluation. Fosun Pharmaceutical ranks second among all listed companies with a comprehensive score of 92 points.

In the evaluation of the social responsibility report, using the social responsibility report issued by Shanghai listed companies in 2016 as a sample, from the completeness, materiality, balance, comparability, readability, and innovation of the corporate social responsibility report&ldquo ;Six characteristics” to systematically evaluate the quality of the report. Fosun Pharma ranks first with a comprehensive score of 93.7, and has excellent performance in comparability and innovation.

In the pharmaceutical and biological industry responsibility development index, Fosun Pharma has a comprehensive score of 92 points. At the same time, in the case of biomedical topic scores, it is in stakeholder communication, responsibility communication, shareholder rights, supply chain management, customer service, and technological innovation. , Operation in accordance with the law, employee care, public welfare and charity, environmental responsibility achieved excellent results. Zhong Hongwu, director of the Corporate Social Responsibility Research Center of the Economics Department of the Chinese Academy of Social Sciences, said in his interpretation of the "Blue Book on Corporate Social Responsibility of Listed Companies in Shanghai" that innovation in the pharmaceutical industry itself is an important manifestation of social responsibility. In the process of interpreting the Blue Book, he took Fosun Pharma's innovative achievements as an example, and emphasized that pharmaceutical industry companies should strengthen their awareness, enhance technological innovation capabilities, pay attention to drug quality and safety, and strengthen information disclosure.

Chen Qiyu, Chairman of Fosun Pharma, said that innovation is the most important social responsibility of pharmaceutical companies. Through innovation, the company should provide patients with more timely diagnosis and treatment, more effective treatment, more efficient supply, more satisfactory service and more affordable payment. Fosun Pharma will actively promote the formulation of higher and stricter sustainable development standards, and set an example, starting from its own company, and constantly purifying the market environment of the entire pharmaceutical industry, thereby triggering a healthier and more sustainable development of the entire industry. .

Fosun Pharma has issued a corporate social responsibility report for the first time since 2009, and has been disclosed every year since then at the same time as the A-share annual report. In 2016, the "2015 Corporate Social Responsibility Report" disclosed by Fosun Pharma was released at the same time as the A-share and H-shares, and the English and Traditional Chinese version was also released on the H-shares at the same time. The report showed the public the measures and progress of Fosun Pharma in strategic management, economic responsibility, product and service quality, environmental protection, occupational health and safety, employee development and social welfare, and elaborated on Fosun Pharma’s sustainable development strategy . SGS, the inspection agency of the report, stated in the inspection statement that the report has improved the sustainable development strategy and social responsibility system, and has provided a benchmark for the pharmaceutical industry. Fosun Pharma's corporate social responsibility report has been repeatedly rated by Runling Global Responsibility Rating “Annual AA+ Grade”, No. 1 in the pharmaceutical industry. In 2016, Fosun Pharma won the "Golden Bee 2016 Excellent Corporate Social Responsibility Report" · Leadership Enterprise Award".

As a leading domestic pharmaceutical and health industry group, Fosun Pharma always takes the promotion of human health as its mission, pursues the principle of sustainable development, and actively undertakes the enterprise from all aspects of strategic management, economic development, products and services, environmental health and safety, etc. Due to social responsibilities, we are committed to creating a more harmonious industry ecosystem.